Rubius cites some preclinical progress; Xencor scores deal with Astellas; Eidos to restate quarterly filings
→ Rubius Therapeutics $RUBY has posted some positive — though preclinical — study results on its red blood cell tech, saying they were able to track a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
